ReviewCurrent hypertension reports2024
Cell-Free Nucleic Acids for Early Prediction of Preeclampsia.
Review in Current hypertension reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Maternal cell-free DNA in early pregnancy for preeclampsia screening: a systematic review.Archives of gynecology and obstetrics · 2025Pooled it
- First-trimester multi-modal cell-free DNA analysis for prediction of preterm and term preeclampsia.AJOG global reports · 2026Article
- Cell-Based and Cell-Free Non-Invasive Prenatal Analysis of Preeclampsia: An Updated Review of Liquid Biopsy.Biomedicines · 2026Review
- Cell-free RNAs in maternal peripheral blood as potential biomarkers of preeclampsia: a review.Reproductive biology and endocrinology : RB&E · 2025Review
- Liquid Biopsy and Single-Cell Technologies in Maternal-Fetal Medicine: A Scoping Review of Non-Invasive Molecular Approaches.Diagnostics (Basel, Switzerland) · 2025Review
- Advancing diagnosis and early risk assessment of preeclampsia through noninvasive cell-free DNA methylation profiling.Clinical epigenetics · 2024Article
- Unlocking Early Cancer Detection: Leveraging Machine Learning in Cell-Free DNA Analysis for Precision Oncology.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024Article
- Non-invasive prediction of preeclampsia using the maternal plasma cell-free DNA profile and clinical risk factors.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review summarizes the potential of cell-free nucleic acids for predicting preeclampsia, contrasts them with other methods, and discusses these findings' relevance to preeclampsia's pathogenesis and care. RECENT
findingsRecent studies have demonstrated the utility of cell-free nucleic acids in early preeclampsia risk prediction. Encouragingly, nucleic acid measurement exhibits similar or better sensitivity as compared to standard screening assays and furthermore sheds light on preeclampsia's underlying placental biology. Over the past decade, liquid biopsies measuring cell-free nucleic acids have found diverse applications, including in prenatal care. Recent advances have extended their utility to predict preeclampsia, a major cause of maternal mortality. These assays assess methylation patterns in cell-free DNA (cfDNA) or gene levels in cell-free RNA (cfRNA). Currently, preeclampsia care focuses on blood pressure control, seizure prevention, and delivery. If validated, early prediction of preeclampsia through liquid biopsies can improve maternal health and deepen our understanding of its causes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.